Topical and systemic medications for the treatment of primary Sjögren's syndrome

被引：0
作者：
Manuel Ramos-Casals
Pilar Brito-Zerón
Antoni Sisó-Almirall
Xavier Bosch
Athanasios G. Tzioufas
机构：
[1] Sjögren's Syndrome Research Group (AGAUR),Department of Autoimmune Diseases
[2] Laboratory of Autoimmune Diseases Josep Font,Department of Internal Medicine
[3] Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Department of Pathophysiology
[4] Hospital Clínic,undefined
[5] University of Barcelona,undefined
[6] Institut Clínic de Medicina i Dermatologia (ICMiD),undefined
[7] Hospital Clínic,undefined
[8] University of Barcelona,undefined
[9] Primary Care Research Group,undefined
[10] IDIBAPS,undefined
[11] University of Barcelona,undefined
[12] CAP Les Corts,undefined
[13] GESCLINIC,undefined
[14] School of Medicine,undefined
[15] University of Athens,undefined
来源：
Nature Reviews Rheumatology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Both sicca and systemic symptoms affect quality of life in patient with Sjögren's syndrome, and their management is complicated by the low level of evidence supporting the available therapeutic options. Here, the authors comprehensively review the data on the efficacy of treatments for the glandular and extraglandular manifestations of this disease. Ramos-Casals and colleagues also recommend treatment approaches tailored to different clinical scenarios that patients with Sjögren's syndrome can present.
引用
收藏
页码：399 / 411
页数：12
相关论文
共 283 条
[31]  
Vissink A(2008)Evaluation of topical cyclosporine for the treatment of dry eye disease Arch. Ophthalmol. 126 1046-1050
[32]  
Aragona P(2000)Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group Ophthalmology 107 631-639
[33]  
Di Stefano G(2009)A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome Am. J. Ophthalmol. 147 206-213
[34]  
Ferreri F(2005)Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years Ophthalmology 112 1790-1794
[35]  
Spinella R(2004)Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye Cornea 23 784-792
[36]  
Stilo A(1986)Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem Scand. J. Rheumatol. Suppl. 61 250-252
[37]  
Aragona P(1989)A follow-up study of the progress of keratoconjunctivitis sicca and response to treatment in primary Sjögren's syndrome Scand. J. Rheumatol. 18 193-196
[38]  
Papa V(1986)A double-blind, cross-over, study of oral Scand. J. Rheumatol. Suppl. 61 253-258
[39]  
Micali A(2007)-acetylcysteine in Sjögren's syndrome Oral Dis. 13 88-92
[40]  
Santocono M(2006)Pilocarpine treatment in a mixed cohort of xerostomic patients Br. J. Ophthalmol. 90 166-170
12345678910